Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
A phase 3 trial of Olaparib in ovarian cancer, run by AstraZeneca, active and no longer recruiting.
Overview
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy is a phase 3 interventional study registered as NCT01874353 by AstraZeneca, with 327 participants enrolled, started 2013-09-03 and due to reach its primary completion in 2016-09-19. Interventions recorded: Olaparib 300mg tablets and Placebo to match olaparib 300mg. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialEfficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Shares Olaparib, Merck & Co. (MSD), AstraZeneca and the tag pipeline.
- TrialStudy of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
Shares Olaparib, AstraZeneca and the tag pipeline.
- TrialA Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
Shares Olaparib, AstraZeneca and the tag pipeline.
- TrialA Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
Shares Olaparib, AstraZeneca, Ovarian cancer and the tag pipeline.
- TrialRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Shares Olaparib, AstraZeneca, Ovarian cancer.
- TrialD9319C00001- 1L OC Mono Global RCT
Shares Olaparib, AstraZeneca, Ovarian cancer.
- TrialStudy of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Shares Olaparib and the tag pipeline.
- TrialA Trial of Vigil for Participants With Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.